137,400 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by Swedbank AB

Swedbank AB purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 137,400 shares of the biotechnology company's stock, valued at approximately $16,706,000. Swedbank AB owned 0.14% of Sarepta Therapeutics as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC boosted its position in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock valued at $340,527,000 after purchasing an additional 665,087 shares during the period. Geode Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after buying an additional 44,306 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Sarepta Therapeutics by 9.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company's stock valued at $94,148,000 after buying an additional 63,437 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new stake in Sarepta Therapeutics in the third quarter valued at $79,425,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Activity

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on SRPT. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Guggenheim upped their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Raymond James restated an "outperform" rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Robert W. Baird dropped their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. Finally, Evercore ISI cut their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $178.71.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded up $0.45 during midday trading on Tuesday, reaching $114.26. 287,389 shares of the company were exchanged, compared to its average volume of 812,892. Sarepta Therapeutics, Inc. has a one year low of $102.15 and a one year high of $173.25. The stock's 50-day moving average price is $122.78 and its 200-day moving average price is $126.72. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market cap of $10.91 billion, a P/E ratio of 91.43 and a beta of 0.75.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.